Lorvotuzumab Biosimilar – Anti-NCAM1, CD56 mAb – Research Grade

Description of Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb - Research Grade

Introduction

Lorvotuzumab Biosimilar, also known as Anti-NCAM1 or CD56 monoclonal antibody, is a research grade antibody that has shown promising results in the treatment of various types of cancer. In this article, we will delve into the structure, activity and potential applications of this antibody.

Structure

Lorvotuzumab Biosimilar is a humanized monoclonal antibody that specifically targets the neural cell adhesion molecule 1 (NCAM1) or CD56. It is composed of two heavy chains and two light chains, each containing a variable and a constant region. The variable region is responsible for binding to the target antigen, while the constant region determines the antibody’s effector functions.

Activity

NCAM1 or CD56 is a glycoprotein that is highly expressed on the surface of various types of cancer cells, including small cell lung cancer, multiple myeloma, and neuroblastoma. It plays a crucial role in cell adhesion, migration, and proliferation, making it an attractive therapeutic target for cancer treatment.

Lorvotuzumab Biosimilar binds to NCAM1 or CD56 with high specificity and affinity, leading to the activation of various immune mechanisms that can destroy cancer cells. These mechanisms include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis.

In addition, Lorvotuzumab Biosimilar has also been shown to inhibit the growth and spread of cancer cells by blocking the interaction between NCAM1 or CD56 and other molecules involved in cancer progression.

Applications

Lorvotuzumab Biosimilar has shown promising results in preclinical and clinical studies as a potential treatment for various types of cancer. Here are some of the potential applications of this antibody:

1. Small Cell Lung Cancer (SCLC)

SCLC is an aggressive form of lung cancer that is associated with poor prognosis and limited treatment options. NCAM1 or CD56 is highly expressed on SCLC cells, making it an ideal target for Lorvotuzumab Biosimilar. In a phase II clinical trial, this antibody showed promising results in combination with chemotherapy, leading to improved overall survival and progression-free survival in patients with SCLC.

2. Multiple Myeloma

Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. NCAM1 or CD56 is highly expressed on the surface of multiple myeloma cells and is associated with disease progression and poor prognosis. In a phase I/II clinical trial, Lorvotuzumab Biosimilar in combination with other therapies showed promising results in patients with relapsed or refractory multiple myeloma.

3. Neuroblastoma

Neuroblastoma is a type of cancer that affects the nervous system, primarily in children. NCAM1 or CD56 is highly expressed on neuroblastoma cells and is associated with disease progression and poor prognosis. In a phase II clinical trial, Lorvotuzumab Biosimilar in combination with chemotherapy showed promising results in patients with relapsed or refractory neuroblastoma.

4. Other Cancers

Apart from the above-mentioned cancers, Lorvotuzumab Biosimilar is also being investigated as a potential treatment for other types of cancer, including ovarian cancer, breast cancer, and pancreatic cancer. NCAM1 or CD56 is expressed on the surface of cancer cells in these types of cancer, making it a potential therapeutic target for Lorvotuzumab Biosimilar.

Conclusion

Lorvotuzumab Biosimilar, also known as Anti-NCAM1 or CD56 monoclonal antibody, is a promising research grade antibody that specifically targets NCAM1 or CD56, a glycoprotein highly expressed on the surface of various types of cancer cells. Its high specificity and affinity make it an attractive therapeutic option for the treatment of cancer. Clinical trials have shown promising results in various types of cancer, and further research is ongoing to explore its potential in other types of cancer.

SDS-PAGE for Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb

Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb binds to CD56 Recombinant Protein in indirect ELISA Assay

Immobilized CD56 Recombinant Protein (cat. No.PX-P4123) at 0.5µg/mL (100µL/well) can bind to Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb (cat. No.PX-TA1047) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450